Paraaortic Extra-Adrenal Paraganglioma: Challenging Robotic Resection.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
13 Apr 2024
Historique:
received: 22 01 2024
accepted: 25 03 2024
medline: 14 4 2024
pubmed: 14 4 2024
entrez: 13 4 2024
Statut: aheadofprint

Résumé

Up to 41% of intra- and extra-adrenal paragangliomas are linked to germline mutations with autosomal dominant transmission, which necessitates genetic testing for patients and their relatives. We present a multimedia article featuring a step-by-step video of a complex retroperitoneal resection, enriched with perioperative management insights. A 17-year-old female presented with episodes of hypertension, tachycardia, and diffuse diaphoresis. CT revealed a paraaortic mass adjacent to the left renal hilum later confirmed by a SPECT/CT with iodine-123 meta-iodobenzylguanidine. Robotic-assisted resection can be safe and effective for retroperitoneal malignant paragangliomas. However, management extends beyond surgery and requires cascade genetic testing to address familial risks. Because of the high probability of cancer associated with SDHB mutation, lifelong patient surveillance is imperative.

Sections du résumé

BACKGROUND BACKGROUND
Up to 41% of intra- and extra-adrenal paragangliomas are linked to germline mutations with autosomal dominant transmission, which necessitates genetic testing for patients and their relatives.
METHODS METHODS
We present a multimedia article featuring a step-by-step video of a complex retroperitoneal resection, enriched with perioperative management insights.
RESULTS RESULTS
A 17-year-old female presented with episodes of hypertension, tachycardia, and diffuse diaphoresis. CT revealed a paraaortic mass adjacent to the left renal hilum later confirmed by a SPECT/CT with iodine-123 meta-iodobenzylguanidine.
CONCLUSIONS CONCLUSIONS
Robotic-assisted resection can be safe and effective for retroperitoneal malignant paragangliomas. However, management extends beyond surgery and requires cascade genetic testing to address familial risks. Because of the high probability of cancer associated with SDHB mutation, lifelong patient surveillance is imperative.

Identifiants

pubmed: 38615151
doi: 10.1245/s10434-024-15267-z
pii: 10.1245/s10434-024-15267-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. Society of Surgical Oncology.

Références

Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. New Engl J Med. 2002;346(19):1459–66.
doi: 10.1056/NEJMoa020152 pubmed: 12000816
Mannelli M, Castellano M, Schiavi F, et al. Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab. 2009;94(5):1541–7.
doi: 10.1210/jc.2008-2419 pubmed: 19223516
Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL. Inherited mutations in pheochromocytoma and paraganglioma: Why all patients should be offered genetic testing. Ann Surg Oncol. 2013;20(5):1444–50.
doi: 10.1245/s10434-013-2942-5 pubmed: 23512077 pmcid: 4291281
Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552–65.
doi: 10.1056/NEJMra1806651 pubmed: 31390501
Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91(11):4505–9.
doi: 10.1210/jc.2006-0423 pubmed: 16912137
Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat. 2010;31(1):41–51.
doi: 10.1002/humu.21136 pubmed: 19802898
Srirangalingam U, Walker L, Khoo B, et al. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol. 2008;69(4):587–96.
doi: 10.1111/j.1365-2265.2008.03274.x
Lee KY, Oh YW, Noh HJ, et al. Extraadrenal paragangliomas of the body: imaging features. AJR Am J Roentgenol. 2006;187(2):492–504.
doi: 10.2214/AJR.05.0370 pubmed: 16861555
Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Gen. 2001;69(1):49–54.
doi: 10.1086/321282
Else T, Greenberg S, Fishbein L. Hereditary Paraganglioma-Pheochromocytoma Syndromes. In: Adam MP, Feldman J, Mirzaa GM, et al. (eds.) GeneReviews®. Seattle (WA): University of Washington, Seattle Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved; 1993. 2008 May 21 [updated 2023 Sep 21].

Auteurs

Andrei Nikiforchin (A)

Surgical Oncology, Marshfield Medical Center, Marshfield, WI, USA.

Ekaterina Baron (E)

Surgical Oncology, Marshfield Medical Center, Marshfield, WI, USA.

Jessica A Wernberg (JA)

Surgical Oncology, Marshfield Medical Center, Marshfield, WI, USA.

Rohit Sharma (R)

Surgical Oncology, Marshfield Medical Center, Marshfield, WI, USA. sharma.rohit@marshfieldclinic.org.

Classifications MeSH